We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+34.73%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$612M
AUM Growth
+$82.6M
Cap. Flow
+$22.2M
Cap. Flow %
3.63%
Top 10 Hldgs %
69.92%
Holding
102
New
27
Increased
15
Reduced
11
Closed
43

Top Buys

Rank Stock Value
1
GYRE icon
Gyre Therapeutics
GYRE
+$17.5M
2
ARWR icon
Arrowhead Research
ARWR
+$10.9M
3
ARGX icon
argenx
ARGX
+$6.1M
4
RCKT icon
Rocket Pharmaceuticals
RCKT
+$5.71M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$5.57M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$14.7M
2
ZGNX
Zogenix, Inc.
ZGNX
+$12M
3
PDSB icon
PDS Biotechnology
PDSB
+$8.84M
4
EVH icon
Evolent Health
EVH
+$5.17M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$4.42M

Sector Composition

Rank Sector Weight
1 Healthcare 61.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTR icon
76
PUT
Nektar Therapeutics
NKTR
$2.47B
– –
-2,000
Closed -$1.79M
NTLA icon
77
CALL
Intellia Therapeutics
NTLA
$1.53B
– –
-86,000
Closed -$1.65M
PDSB icon
78
PDS Biotechnology
PDSB
$40.6M
– –
-47,195
Closed -$8.84M
RARE icon
79
CALL
Ultragenyx Pharmaceutical
RARE
$2.46B
– –
-46,000
Closed -$2.13M
TDOC icon
80
PUT
Teladoc Health
TDOC
$1.26B
– –
-40,000
Closed -$1.39M
TGTX icon
81
CALL
TG Therapeutics
TGTX
$7.64B
– –
-10,000
Closed -$82K
NVTA
82
DELISTED
Invitae Corporation
NVTA
– –
-152,300
Closed -$1.38M
SGEN
83
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-80,000
Closed -$4.28M
SGEN
84
PUT
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-30,000
Closed -$1.6M
VRAY
85
CALL
DELISTED
ViewRay, Inc.
VRAY
– –
-120,000
Closed -$1.11M
GBT
86
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-80,000
Closed -$3.15M
FPRX
87
PUT
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-52,500
Closed -$1.15M
NEOS
88
CALL
DELISTED
Neos Therapeutics, Inc
NEOS
– –
-115,500
Closed -$1.18M
NEOS
89
PUT
DELISTED
Neos Therapeutics, Inc
NEOS
– –
-25,000
Closed -$255K
MNTA
90
CALL
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-46,300
Closed -$646K
MNTA
91
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-311,169
Closed -$4.34M
MNTA
92
PUT
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-2,500
Closed -$35K
STML
93
CALL
DELISTED
Stemline Therapeutics, Inc.
STML
– –
-105,000
Closed -$1.64M
AVEO
94
CALL
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
– –
-1,200
Closed -$33K
AVEO
95
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
– –
-12,434
Closed -$347K
MDCO
96
CALL
DELISTED
Medicines Co
MDCO
– –
-40,000
Closed -$1.09M
ONCE
97
PUT
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
– –
-10,000
Closed -$514K
LOXO
98
PUT
DELISTED
Loxo Oncology, Inc
LOXO
– –
-30,000
Closed -$2.52M
JUNO
99
CALL
DELISTED
Juno Therapeutics, Inc.
JUNO
– –
-37,000
Closed -$1.69M
ZGNX
100
DELISTED
Zogenix, Inc.
ZGNX
– –
-300,000
Closed -$12M
1 2 3
4
5

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return
POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return

Acuta Capital Partners's Q1 2018 Portfolio in Review

As of Q1 2018, Acuta Capital Partners held 102 positions worth $612M, up 16% from $530M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Acuta Capital Partners deployed $22.2M of net new capital in Q1 2018, opening 27 new positions and adding to 15 existing holdings. Its largest new stake was Arrowhead Research: 1,762,206 shares worth $12.7M.

By sector, the portfolio is most concentrated in Healthcare at 61% of assets, up from 52% a quarter earlier.

On the sell side, the largest reduction was Immunomedics Inc, an estimated $14.7M trimmed.

  • Acuta Capital Partners's largest Q1 2018 buy was Arrowhead Research: 1,762,206 shares worth $12.7M.
  • Acuta Capital Partners added most to Gyre Therapeutics in Q1 2018, an estimated $17.5M increase.
  • Acuta Capital Partners's biggest Q1 2018 reduction was Immunomedics Inc, cutting an estimated $14.7M.
  • Acuta Capital Partners fully exited Zogenix, Inc. in Q1 2018, selling an estimated $12M.
  • Acuta Capital Partners's ten largest holdings make up 70% of its $612M portfolio in Q1 2018.
  • Acuta Capital Partners opened 27 new positions and closed 43 in Q1 2018.
  • Acuta Capital Partners's portfolio value rose 16% quarter-over-quarter to $612M.

Based on Acuta Capital Partners's 13F filing for Q1 2018, filed 15 May 2018.